Search results for: 'drug tech eu'

09 Sep 2024  |  Global  |  Technology Research

AI-based Drug Repurposing Market, Growth Opportunities, Global, 2024-2029

AI-based Drug Repurposing is emerging as a new and faster approach to bringing drugs to patients.

Infographics

×

This study analyzes the emergence of AI-based drug repurposing and examines the factors driving and hindering adoption. The limitation of traditional drug discovery has led to the growing interest in AI -based drug repurposing, which offers numerous advantages in terms of time, speed, and cost. AI-based drug repurposing has been explored across dif...

20 Feb 2020  |  Europe  |  Market Outlook

EU Healthcare Predictions and Outlook, 2020

Rise in Orphan Drug R&D Pipeline, AI-based Funding, and Growth in Biocontract Manufacturing to be Key Drivers of Growth

Infographics

×

Amid rising global trade tensions and sluggish global economic outlook for 2020, the global healthcare market is expected to cross the 2-trillion-dollar mark in 2020. In Europe, BREXIT is likely to have a strong impact on the United Kingdom, Europe's biggest digital health market. 2020 will be a global reality check for long-pending national health...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) encompasses insights across advances in targeted neurological therapies, cancer treatments, and AI-powered drug development. The TOE also features innovators for treatment of metabolic diseases such as obesity and heart failure.The Life Science, Health & Wellnes...

The Transformational Health team at Frost & Sullivan provides critical insights into the US and EU upstream bioprocessing market, highlighting drug demand trends, installed capacity developments, market revenue forecast by various segments, competitive landscape, and key growth opportunities that currently exist or are set to develop during the for...

28 Aug 2020  |  Global  |  Technology Research

Data Science Impacting the Pharmaceutical Industry

Part I: Drug Discovery Applications

Infographics

×

Data science and AI have the potential to transform drug discovery in terms of costs, speed and efficiency. With explosion in biomedical data, data sharing and analysis platforms have surged. AI technologies are moving to the next phase of advancements, and when combined with other emerging tech areas, AI is expected to witness a full fledged adopt...

24 Aug 2021  |  North America  |  Market Research

US and EU Biotech Industry VC Investment Growth Opportunities

Future Growth Potential Driven by Next-generation Cell and Gene Platform Technology Powered by AI

Infographics

×

With this research service, Frost & Sullivan provides critical insights into the biotech, and cell and gene therapy (CGT) venture capital (VC) investment trends highlighting the growth opportunities, key countries in the VC environment, and major trends in cell and gene therapy segment. The study also identifies actionable growth opportunities for ...

Drug device combination products are aimed to provide targeted treatment, enable better drug delivery and improve the efficacy of the device and medicine. This research service (RS) showcases some of these emerging drug-device combination products including drug eluting stents and drug loaded /coated orthopedic implants under implantable drug-devic...

25 Apr 2022  |  North America  |  Frost Radar

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phase...

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...